The U.S. Army Medical Research Acquisition Activity on behalf of the Walter Reed Army Institute of Research (WRAIR) is conducting market research to determine availability of companies who can perform a continuation in the evaluation of neuroprotective agents that make it possible to assess injury severity and to predict outcomes as well as macrophage cell tracking and structural imaging through an outcome measurement of Magnetic Resonance Imaging (MRI) in mild traumatic brain injury (mTBI) in accordance with a WRAIR animal model using Johns Hopkins University School of Medicine Dendrimer-drug Nanoparticle Therapy (US patent #8,889,101, Awarded 2014). THIS IS A SOURCES SOUGHT SYNOPSIS ONLY. THERE IS NO SOLICITATION AVAILABLE AT THIS TIME. PROPOSALS ARE NOT REQUIRED AT THIS TIME AND WILL NOT BE CONSIDERED. Any information submitted is voluntary. The Government will not pay for any information that is submitted in response to this sources sought synopsis. Respondents having proven capability of satisfying the requirements stated herein should provide a narrative identifying business size (large business, small business, and small disadvantaged business, etc.), applicable designators (service-disabled veteran-owned, HUBZone, woman-owned, etc.), experience performing the same or similar services and General Services Administration/Federal Supply Schedule information, if applicable. All responses must be received by Thursday, August 28, 2015. TELEPHONE INQUIRIES SHALL NOT BE ACCEPTED. Narratives should be e-mailed to Mrs. Donna Blackstone at [email protected].

Bid Protests Not Available